Less Ads, More Data, More Tools Register for FREE

Pin to quick picksXaar Regulatory News (XAR)

Share Price Information for Xaar (XAR)

Share Price is delayed by 15 minutes
Get Live Data
144.00    -1.00 (-0.69%)
Bid:
144.00
Ask:
145.00
Spread: 1.00 (0.694%)
Market Cap: £113.00m
XAR Live PriceLast checked at - London Stock Exchange

Intraday Xaar Share Chart

Board Change

23 Feb 2024 10:30

RNS Number : 1814E
Xaar PLC
23 February 2024
 

23 February 2024

Xaar plc

Board Change

Xaar plc, ("the Company" or "Xaar"), a leading inkjet printing technology group, announces today the appointment of Stuart Widdowson to the Board as a Non-Executive Director effective from 27 February 2024.

Mr Widdowson is appointed as a representative of Odyssean Capital LLP ("Odyssean"), pursuant to a relationship agreement between the Company and Odyssean. The key terms are summarised in the notes below.

Mr Widdowson is the Managing Partner of Odyssean Capital, which he founded in 2017. From 2009 until 2017, he was lead fund manager of Strategic Equity Capital plc, which experienced a turnaround in its performance and rating during his tenure. He began his career as a strategy consultant undertaking commercial due diligence and strategy projects for private equity and corporate clients, before working for HgCapital, a leading private equity investor.

As at the last practicable date the total shareholding of funds managed by Odyssean Capital was 13,175,000 ordinary shares in the Company ("Ordinary Shares") representing approximately 16.6 per cent. of the Company's share capital. Additionally, Mr Widdowson beneficially owns 25,000 Ordinary Shares and the joint venture partner of Odyssean Capital, Harwood Capital, owns 1,050,000 Ordinary Shares.

Notes:

A summary of the key terms of the Relationship Agreement is as follows:

· Xaar has granted Odyssean the right to appoint Mr Widdowson to be a Director of the Company for appointment to the Board (the "Nominated Director") for so long as Odyssean has the right to exercise at least 10% or more of the Company's ordinary shares or voting rights attaching to the ordinary shares;

· Odyssean undertakes to, inter alia: (1) conduct all transactions and relationships with any member of Xaar's group on an arm's length basis; (2) not take any action which would have the effect of preventing Xaar or any member of Xaar's group from carrying on business independently of Odyssean or its associates; (3) not influence the day-to-day running of the Company (save through Mr Widdowson's role as the Nominated Director) and (4) not vote to prevent Xaar being managed in accordance with the principles of good governance set out in the UK Corporate Governance Code; and

· the Relationship Agreement will terminate (1) on the date upon which Odyssean ceases to hold at least 10% of the ordinary shares of the Company or the voting rights attaching to the ordinary shares of the Company; (2) on six months' notice written notice by either party at any time or immediately upon written notice in the event of a material breach of the Relationship Agreement; or (3) in the event that the Company's ordinary shares cease to be listed on the Official List or another recognised UK stock exchange.

Pursuant to Listing Rule 9.6.13, it is confirmed that Mr Widdowson was a director and shareholder of Durendal Limited, a fund management business, which was wound up in 2015. His shareholding was acquired by the majority shareholder and the cash was distributed to all shareholders before the company was voluntarily liquidated.

There is no additional information required to be disclosed pursuant to Listing Rule 9.6.13 in relation to the appointment of Stuart Widdowson to the Board.

Enquiries:

Xaar plc

+44 (0) 1223 423 663 

Ian Tichias, Chief Financial Officer

John Mills, Chief Executive Officer

 

Teneo Communications

Giles Kernick

Olivia Lucas

+44 (0) 207 353 4200

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
BOATTMPTMTTTBFI
Date   Source Headline
3rd Feb 20254:15 pmRNSTotal Voting Rights
22nd Jan 202512:30 pmRNSBlock listing Interim Review
21st Jan 20253:00 pmRNSHolding(s) in Company
15th Jan 20257:00 amRNSTrading update & notification of full year results
15th Jan 20257:00 amRNSAppointment of Chief Financial Officer
11th Dec 202410:30 amRNS2024 Full Year Trading Update
4th Dec 202410:45 amRNSUpdate statement on 2024 AGM voting results
3rd Dec 202410:50 amRNSTotal Voting Rights
20th Nov 20247:00 amRNSBoard changes
1st Nov 202412:00 pmRNSTotal Voting Rights
1st Oct 202411:30 amRNSTotal Voting Rights
18th Sep 20247:00 amRNSInterim Results
2nd Sep 20241:45 pmRNSTotal Voting Rights
2nd Aug 20242:30 pmRNSHolding(s) in Company
1st Aug 202411:15 amRNSTotal Voting Rights
30th Jul 20247:00 amRNSNOTICE OF RESULTS AND UPDATE ON TRADING
3rd Jul 202411:45 amRNSBlock listing Interim Review
2nd Jul 20242:00 pmRNSTotal Voting Rights
28th Jun 202410:00 amRNSDirector Declaration
3rd Jun 20242:45 pmRNSTotal Voting Rights
30th May 202412:00 pmRNSBoard changes
29th May 20241:45 pmRNSResult of AGM
29th May 20249:30 amRNSHolding(s) in Company
21st May 20249:30 amRNSDirector/PDMR Shareholding
20th May 20244:30 pmRNSDirector/PDMR Shareholding
13th May 20249:42 amRNSHolding(s) in Company
1st May 20244:15 pmRNSTotal Voting Rights
30th Apr 20244:30 pmRNSDirector/PDMR Shareholding
22nd Apr 202410:51 amRNSAnnual Financial Report
2nd Apr 202412:00 pmRNSTotal Voting Rights
1st Mar 202410:15 amRNSTotal Voting Rights
26th Feb 20249:00 amRNSHolding(s) in Company
23rd Feb 202410:30 amRNSBoard Change
1st Feb 20241:32 pmRNSTotal Voting Rights
29th Jan 202412:04 pmRNSHolding(s) in Company
12th Jan 20243:15 pmRNSBlock listing Interim Review
12th Jan 20247:00 amRNSNotification of Results & Full year Guidance
8th Jan 202412:36 pmRNSTotal Voting Rights
12th Dec 20239:00 amRNSNotification of Transactions of Directors & PDMRs
11th Dec 20233:00 pmRNSNotification of Transactions of Directors & PDMRs
1st Dec 202311:00 amRNSTotal Voting Rights
1st Dec 202310:00 amRNSDirector Declaration
29th Nov 20237:00 amRNSTrading Update
17th Nov 20234:07 pmRNSHolding(s) in Company
9th Nov 20231:53 pmRNSDirector/PDMR Shareholding
3rd Nov 202310:52 amRNSHolding(s) in Company
1st Nov 20234:03 pmRNSTotal Voting Rights
30th Oct 20237:00 amRNSBoard Changes
2nd Oct 202311:45 amRNSTotal Voting Rights
21st Sep 20233:16 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.